Please insert the following paragraph as the first paragraph on page 4 of the specification.

Page 4, paragraph 1 (AMENDED)

B2

from the group comprising nourishing and cordial agents, antipyretic-anodyne-anti-inflammatory drugs, psychotropics, antianxiety drugs, antidepressants, hypnotic-sedative drugs, spasmolytics, central nervous system drugs, brain metabolism ameliorating agents, brain circulation ameliorating agents, antiepileptics, sympathomimetics, gastrointestinal agents, antacids, antiulcer agents, antitussive-expectorants, antiemetics, respiratory accelerators, bronchodilators, antiallergic drugs, dental buccal drugs, antihistamines, cardiotonics, antiarrythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, antihypolipidemic agents, cholagogues, antibiotics, chemotherapeutic drugs, antidiabetic agents, drugs for osteoporosis, antirheumatism agents, skeletal muscle relaxants, antivertigos, hormones, alkaloid narcotics, sulfa drugs, arthrifuges, blood coagulation inhibitors, antitumor agents, drugs for Alzheimer's disease and the like are exemplified.

Please insert the following paragraph as the thirteenth paragraph on page 5 of the specification.

Page 5, paragraph 13 (AMENDED)

B3

As the antitussive expectorants, for instance, chloperastine hydrochloride,

Please insert the following paragraph as the seventh paragraph on page 8 of the specification.

Page 8, paragraph 7 (AMENDED)

B4

Among the above pharmacologically active ingredients, nourishing and cordial agents, antipyretic-anodyne-anti-inflammatory drugs, hypnotic-sedative drugs, central nervous system drugs, gastrointestinal agents, antiulcer agents, antitussive-expectorants, antiallergic drugs,

B4 antiarrythmic drugs, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, antihypolipidemic agents, antidiabetic agents, drugs for osteoporosis, skeletal muscle relaxants, antivertigos and the like are exemplified.

Please insert the following paragraph as the fifth paragraph on page 10 of the specification.

Page 10, paragraph 5 (AMENDED)

B5 Concretely, for example, raw material pulp such as wood pulp and cotton linter is immersed in 10 to 50% concentration of an aqueous solution of sodium hydroxide, and pressed to obtain the alkaline cellulose of which NaOH/cellulose ratio is 0.1 to 1.2 (ratio by weight). Next, the crude low-substituted hydroxypropylcellulose containing free

Please insert the following paragraph as the second paragraph on page 11 of the specification.

Page 11, paragraph 2 (AMENDED)

B6 The crude low-substituted hydroxypropylcellulose containing free alkaline is dispersed in water or hot water containing 5 to 80 % of acid which is necessary to neutralize the total amount of alkaline, and a part of the crude low-substituted hydroxypropylcellulose containing free alkaline is dissolved therein. Further, acid is added to neutralize the remaining alkaline.

Please insert the following paragraph as the fifth paragraph on page 13 of the specification.

Page 13, paragraph 5 (AMENDED)

B7 As the flavorants, for example, lemon, lemon lime, orange, menthol, strawberry and the like are exemplified.

Please insert the following paragraph as the first paragraph on page 27 of the specification.

Page 27, paragraph 1 (AMENDED)

B8

The oral disintegration time of the rapidly disintegrable solid preparation of the present invention (the time for healthy male or female adults to complete disintegration by buccal saliva) is usually 5 to 50 seconds, preferably 5 to 40 seconds, more preferably 5 to 35 seconds.

Please insert the following paragraph as the third paragraph on page 29 of the specification.

Page 29, paragraph 3 (AMENDED)

When manidipine hydrochloride is used as the pharmacologically active ingredient, the rapidly disintegrable solid preparation of the present invention is useful for treatment and

B9

prevention of circulatory system diseases such as hypertension, ischemic heart disease (e.g. angina pectoris, myocardial infarction and the like), cerebral and peripheral circulatory disorders (e.g., cerebral infarction, transient ischemic attack, constriction of renal artery and the like) and the like. The dosage amount of the preparation per an adult (body weight: 60 kg) is 1 to 200 mg/day, preferably 10 to 20 mg/day, as manidipine hydrochloride. The rapidly disintegrable solid preparation is usually administered once a day after breakfast.

In the Claims

Please substitute the following claims 10-12, 18 and 19 for the claims 10-12, 18 and 19 now pending in the above-identified application.

Please add new claim 20.